Market Research Report
Physician Views: CMS guidance on biosimilar reimbursement - what do oncologists and rheumatologists think?
|Published by||FirstWord||Product code||328748|
Delivery time: 1-2 business days
|Physician Views: CMS guidance on biosimilar reimbursement - what do oncologists and rheumatologists think?|
|Published: April 9, 2015||Content info:||
Recent FDA approval of the first US biosimilar product has spurred the Centers for Medicare and Medicaid Services (CMS) to publish new guidance relating to biosimilar reimbursement and usage (ViewPoints: New CMS documents should grease the wheels of adoption for biosimilars) .
Under Medicare Part B, where products are administered by physicians, the CMS has provided clarification on how biosimilars will be reimbursed: at the average sales price (ASP) of the biosimilar in question plus 6 percent of the ASP of the equivalent branded reference product. This guidance is designed to remove a disincentive for a physician to prescribe a biosimilar. As a result, biosimilars and equivalent branded products will have separate billing codes under Medicare Part B.
Under Part D schemes - for pharmacy administered products - new CMS guidance considers a biosimilar and its equivalent branded reference product to be the same, meaning that a branded product could effectively be replaced with a biosimilar (assuming the plan in question maintains access to two products within a drug class). It has been suggested that this decision implies potential 'de facto' interchangeability status for biosimilars.
To help provide FirstWord Pharma PLUS readers a unique analysis of this development, this week we are polling US-based oncologists and rheumatologists in two separate polls to ascertain initial physician sentiment to the CMS guidance.
In our first poll, focused on Part B reimbursement, we are asking oncologists...
In our second poll, focused on Part D reimbursement, we are asking rheumatologists...
Note : FirstWord Polls are powered by MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialities and over 100 markets.